Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution

This publication has 15 references indexed in Scilit:

• ¹⁸⁶Re-Labeled Antibodies to p185^HER2as HER2-Targeted Radioimmunopharmaceutical Agents: Comparison of Physical and Biological Characteristics with¹²⁵I and¹³¹I-Labeled Counterparts
  Cancer Biotherapy & Radiopharmaceuticals, 1996
• The tyrosine kinase activity of the C‐erbB‐2 gene product (p185) is required for growth inhibition by anti‐p185 antibodies but not for the cytotoxicity of an anti‐p185‐ricin‐a chain immunotoxin
  International Journal of Cancer, 1994
• Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells
  International Journal of Cancer, 1994
• Characterization of cytotoxic activity of saporin anti‐gp185/HER‐2 immunotoxins
  International Journal of Cancer, 1993
• Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)
  Journal of Neuro-Oncology, 1993
• Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbb-2 (her-2/neu) gene product p185
  International Journal of Cancer, 1993
• Rat monoclonal antibodies to the external domain of the product of the C‐erbB‐2 proto‐oncogene
  International Journal of Cancer, 1990
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989
• Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
  Science, 1985
• The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
  Nature, 1984